Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill D-2570 shows promise against stubborn psoriasis in early trial

NCT ID NCT06278350

Completed Disease control Sponsor: InventisBio Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 clinical trial tested an experimental oral drug called D-2570 in 161 adults with moderate-to-severe plaque psoriasis. Participants were randomly assigned to one of three doses of D-2570 or a placebo for 12 weeks. The main goal was to see how many people achieved at least 75% clearer skin. The study is now complete, and results will help determine if D-2570 is safe and effective enough for larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
D-2570
What this could lead to
If successful, D-2570 could offer a new oral treatment option for people with moderate-to-severe plaque psoriasis, helping clear skin and reduce symptoms.
What could go wrong
This is an early phase 2 trial with only 161 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Locations

  • Peking University People's Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.